Therapeutic Asset Ratings

145 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II Renal Cell Carcinoma	Inhibrx Biosciences, Inc	P2	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER Renal Cell Carcinoma	Novartis Pharmaceuticals	P2	B (60)
Carboplatin Renal Cell Carcinoma	Shanghai Henlius Biotech	P2	B (59)
Obinutuzumab Renal Cell Carcinoma	Simcha IL-18, Inc.	P2	B (58)
Calcium folinate pentahydrate Renal Cell Carcinoma	Neonc Technologies, Inc.	P1/2	B (58)
Naptumomab Estafenatox Renal Cell Carcinoma	NeoTX Therapeutics Ltd.	P2/3	B (57)
Zirconium Zr 89 girentuximab deferoxamine Renal Cell Carcinoma	Jonsson Comprehensive Cancer Center	P2/3	B (57)
Avelumab Renal Cell Carcinoma	NRG Oncology	P3	B (56)
Vorolanib Renal Cell Carcinoma	Peking University Cancer Hospital & Institute	P3	B (56)
Tislelizumab Renal Cell Carcinoma	Fudan University	P2	B (56)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Renal Cell Carcinoma	Brian Rini	P2	CCC (55)
Abexinostat Renal Cell Carcinoma	Xynomic Pharmaceuticals, Inc.	P3	CCC (52)
Dc-Cik Renal Cell Carcinoma	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	P2	CCC (52)
Ivonescimab Renal Cell Carcinoma	City of Hope Medical Center	P2	CCC (52)
PIFLUFOLASTAT Renal Cell Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (52)
Relatlimab Renal Cell Carcinoma	The Netherlands Cancer Institute	P2	CCC (52)
Zimberelimab Renal Cell Carcinoma	Dana-Farber Cancer Institute	P2	CCC (52)
Entinostat Renal Cell Carcinoma	Roberto Pili	P2	CCC (51)
Ketorolac Tromethamine Renal Cell Carcinoma	University of Miami	P2	CCC (51)
ALECTINIB Renal Cell Carcinoma	Cancer Research UK	P2/3	CCC (50)
Casdatifan Renal Cell Carcinoma	Dana-Farber Cancer Institute	P2	CCC (48)
Catequentinib Renal Cell Carcinoma	Fujian Cancer Hospital	P2	CCC (48)
DENTALFLUORO Renal Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (48)
Entrectinib Renal Cell Carcinoma	Hoffmann-La Roche	P2	CCC (48)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Renal Cell Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (48)

Showing 26 to 50 of 145 assets

PreviousPage 2 of 6Next